By Ian Maleve
China-based nutraceutical firm aland Health Holding is actively seeking potential buyers for its controlling stake, targeting a valuation above $1.5 billion, according to insider sources.
The company’s founder and chairman, Chang Liang, holds approximately 60 percent of the company, while major investment firms such as Affinity Equity Partners, Goldman Sachs Growth Equity, and Henderson Investment Corp make up the remaining ownership.
The company, which this year is forecasted to generate around $150 million in EBITDA, has drawn early interest from both strategic buyers and private equity firms.
Analysts see aland’s U.S.-based subsidiary, International Vitamin Corporation (IVC), as a key asset enhancing the firm’s attractiveness. IVC’s U.S.-based production capabilities are well-positioned to cater to reshoring efforts and rising global demand for wellness and nutritional products.
With eleven manufacturing facilities and four international research and development centers across Asia, North America, and Europe, aland employs over 5,000 staff and maintains robust production scale including more than 30 billion tablets, 9 billion softgels, 6 billion capsules, and 16,000 metric tons of powder annually.
The company serves both branded consumers and notable retailers through private-label arrangements with companies such as Walmart and Costco.
While discussions are still in preliminary stages, insiders confirm that there is no fixed timeline yet for soliciting non-binding offers.
The move underscores broader market dynamics, including a push toward localization of supply chains particularly in sectors like health and wellness, which are experiencing rising demand.
The global nutritional supplements market, valued at approximately $485.6 billion in 2024, is expected to expand significantly to an estimated $704.3 billion by 2030 at a compound annual growth rate of 6.4 percent, reflecting strong long-term prospects for potential buyers.
The intended sale marks a strategic turning point for aland. As the company navigates this early-stage process, stakeholders are closely watching to see whether a final deal will reflect the company’s growing footprint, diversified products, and international reach, or whether valuation expectations will adjust in line with market trends and competitive pressures.
Overall, aland Health’s bid to tap into significant sale value reflects both its current scale and the heightened investor appetite for companies capable of bridging consumer health demand with supply chain resilience.
